SEK608.1m market cap
SEK3.06 last close
Brighter is a Swedish healthtech company addressing common welfare challenges of modern society through a group of innovation companies. Its lead solution, Actiste, currently being commercialised, is aimed at helping people with diabetes adhere to care guidelines and achieve treatment goals.
Investment summary
Brighter is a healthtech company developing solutions for chronic diseases. Its initial strategy is the market introduction of Actiste, a remote monitoring and treatment service for diabetes which recently received two CE marks (Actiste is regulated under both the EU Medical Devices Directive and the In Vitro Diagnostics Directive). The service includes a unique patented device that integrates all the essential features for daily diabetes management, a blood glucose meter, a lancer and an insulin injection pen, into a single unit with built-in mobile connection, and a digital platform for analysing and sharing data with family and friends, healthcare providers and other relevant stakeholders.
Y/E Dec |
Revenue (SEKm) |
EBITDA (SEKm) |
PBT (SEKm) |
EPS (öre) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 1.1 | (44.2) | (48.8) | (74.00) | N/A | N/A |
| 2019A | 3.3 | (73.7) | (88.7) | (105.85) | N/A | N/A |
| 2020E | 24.5 | (115.8) | (141.4) | (71.00) | N/A | N/A |
| 2021E | 133.8 | (29.6) | (55.2) | (27.44) | N/A | N/A |
Industry outlook
In 2017, costs attributed to diagnosed diabetes and associated complications, such as cardiovascular disease and nephropathy, totalled $327bn in the US. Patient opinions of treatment burden are heavily correlated with adherence to self-care.
Last updated on 24/09/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (SEKm) | 56.1 |
| Forecast gearing ratio (%) | 23 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Truls Sjostedt | Chairman |
| Henrik Norström | CEO |
| Anne Zetterberg | CFO |
| Petra Kaur | Chief Commercial and Marketing Officer |
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma